ITUS is an early stage biotechnology company. Through its subsidiary, Anixa Diagnostics Corporation, Co. develops a platform for non-invasive blood tests for the early detection of cancer. That platform is called Cchek™. Co.'s CchekO™ cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence, and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Co. is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling. The ITUS average annual return 10 years is shown above.
The Average Annual Return on the ITUS average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ITUS average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ITUS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
